Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
New York Composite
Gold
Crude Oil
Local Stocks
Stocks of Local Interest
PG Energy Index
Local Stocks
Energy Stocks
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries
Argenx Se Ads
(NQ:
ARGX
)
279.22
USD
-2.95 (-1.05%)
Official Closing Price
Updated: 5:02 PM EST, Jan 15, 2021
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press releases about Argenx Se Ads
< Previous
1
2
Next >
argenx Announces 2021 Corporate Priorities and Highlights Recent Achievements Across Immunology Pipeline
January 08, 2021
From
GlobeNewswire News Releases
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
January 06, 2021
From
GlobeNewswire News Releases
argenx and Zai Lab Announce Strategic Collaboration for Efgartigimod in Greater China
January 06, 2021
From
GlobeNewswire News Releases
argenx to Present at 39th Annual J.P. Morgan Healthcare Conference
January 04, 2021
From
GlobeNewswire News Releases
argenx Enters Into Agreement To Acquire Priority Review Voucher
November 23, 2020
From
GlobeNewswire News Releases
argenx Premieres A Mystery to Me, a Docuseries Inspired by the Myasthenia Gravis Patient Experience
November 17, 2020
-- Created in partnership with Sarofsky Productions, A Mystery to Me explores how three people persevere through the challenges of living with myasthenia gravis, a rare neuromuscular disease
From
PR Newswire
argenx to Participate in Upcoming Virtual Investor Conferences
November 09, 2020
From
GlobeNewswire News Releases
argenx Reports Third Quarter 2020 Financial Results and Provides Business Update
October 22, 2020
From
GlobeNewswire News Releases
argenx to Report Third Quarter 2020 Financial Results and Business Update on October 22, 2020
October 15, 2020
From
GlobeNewswire News Releases
argenx Expands Capabilities In Antibody Engineering Through Key Technology Partnerships
October 06, 2020
From
GlobeNewswire News Releases
argenx Presents Additional Efgartigimod Data from Global Phase 3 ADAPT Trial at the Myasthenia Gravis Foundation of America 2020 Scientific Session
October 05, 2020
From
GlobeNewswire News Releases
argenx Management to Present at Upcoming Virtual Investor Conferences
September 02, 2020
From
GlobeNewswire News Releases
argenx to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
August 04, 2020
From
GlobeNewswire News Releases
argenx reports half year 2020 financial results and provides second quarter business update
July 30, 2020
From
GlobeNewswire News Releases
argenx announces full exercise of underwriters’ option to purchase additional ADSs
May 29, 2020
From
GlobeNewswire News Releases
argenx raises $750 million in gross proceeds in a global offering
May 28, 2020
From
GlobeNewswire News Releases
argenx announces launch of proposed global offering
May 26, 2020
From
GlobeNewswire News Releases
argenx Announces Positive Topline Results from Phase 3 ADAPT Trial of Efgartigimod in Patients with Generalized Myasthenia Gravis
May 26, 2020
From
GlobeNewswire News Releases
argenx reports first quarter 2020 financial results and provides business update
May 14, 2020
From
GlobeNewswire News Releases
argenx reports full year 2019 financial results and provides fourth quarter business update
February 27, 2020
From
GlobeNewswire News Releases
argenx announces closing of global offering
November 12, 2019
From
GlobeNewswire News Releases
argenx announces full exercise of underwriters’ option to purchase additional ADSs
November 08, 2019
From
GlobeNewswire News Releases
argenx raises $484 million in gross proceeds in a global offering
November 06, 2019
From
GlobeNewswire News Releases
argenx reports third quarter 2019 financial results and provides business update
October 24, 2019
From
GlobeNewswire News Releases
argenx to Present at Morgan Stanley 17th Annual Global Healthcare Conference
September 03, 2019
From
GlobeNewswire News Releases
argenx to Present at 2019 Wedbush PacGrow Healthcare Conference
August 06, 2019
From
GlobeNewswire News Releases
argenx reports half year 2019 financial results and second quarter business update
August 01, 2019
From
GlobeNewswire News Releases
argenx to report half year 2019 financial results and second quarter business update on August 1, 2019
July 25, 2019
From
GlobeNewswire News Releases
argenx announces pipeline expansion and “argenx 2021” vision to build integrated immunology company at 2019 R&D Day
May 22, 2019
From
GlobeNewswire News Releases
AgomAb Therapeutics Completes Euros 21m Series A Financing
April 02, 2019
AgomAb Therapeutics N.V. (‘AgomAb’), a privately held Belgian biotherapeutics company developing agonistic antibodies for regeneration of damaged tissues, announces today that it has secured EUR 21m in...
From
Business Wire News Releases
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.